Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 13/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.59 |
| ▸ | TSHR | P16473 | 8/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.59 |
| ▸ | LMNA | P02545 | 12/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27648471 | 0.92 | CLK4 (0.52) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL5186730 | 0.84 | MAPK1 (0.55) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL6181678 | 0.79 | TGFBR1 (0.48) | ALDH1A1MAPK1CYP1A2KDM4EHPGD | |
| SCHEMBL5138195 | 0.78 | MAP4K4 (0.52) | — | |
| SCHEMBL5139502 | 0.77 | MAP4K4 (0.42) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL3845114 | 0.77 | CYP3A4 (0.52) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL5930851 | 0.76 | CLK4 (0.54) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL30734213 | 0.74 | ACHE (0.57) | CLK4CYP2C19HIF1AALDH1A1MAPK1 | |
| SCHEMBL3850901 | 0.74 | DYRK1A (0.41) | CYP2C19ALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL5138085 | 0.74 | TGFBR1 (0.40) | CYP2C19ALDH1A1MAPK1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | CLK4 3573/4885CYP2C19 1377/4885HIF1A 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.